Cargando…
Discovery of Novel Biphenyl Carboxylic Acid Derivatives as Potent URAT1 Inhibitors
Urate transporter 1 (URAT1) is a clinically validated target for the treatment of hyperuricemia and gout. Due to the absence of protein structures, the molecular design of new URAT1 inhibitors generally resorts to ligand-based approaches. Two series of biphenyl carboxylic acids were designed based o...
Autores principales: | Hou, Xianxin, Wang, Yongcheng, Yang, Yajun, Xiao, Zhiyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648204/ https://www.ncbi.nlm.nih.gov/pubmed/37959834 http://dx.doi.org/10.3390/molecules28217415 |
Ejemplares similares
-
Discovery of a Flexible Triazolylbutanoic Acid as a Highly Potent Uric Acid Transporter 1 (URAT1) Inhibitor
por: Tian, He, et al.
Publicado: (2016) -
Discovery of 2-(4-Acrylamidophenyl)-Quinoline-4-Carboxylic Acid Derivatives as Potent SIRT3 Inhibitors
por: Hui, Qian, et al.
Publicado: (2022) -
Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017) -
4′-Hydroxybiphenyl-4-carboxylic acid
por: Feng, Sun
Publicado: (2008) -
Discovery of 2-Phenylquinoline-4-Carboxylic Acid Derivatives as Novel Histone Deacetylase Inhibitors
por: Hui, Qian, et al.
Publicado: (2022)